Asset Details
Do you wish to reserve the book?
The Effects of Strontium Ranelate on the Risk of Vertebral Fracture in Women with Postmenopausal Osteoporosis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
The Effects of Strontium Ranelate on the Risk of Vertebral Fracture in Women with Postmenopausal Osteoporosis
Do you wish to request the book?
The Effects of Strontium Ranelate on the Risk of Vertebral Fracture in Women with Postmenopausal Osteoporosis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
The Effects of Strontium Ranelate on the Risk of Vertebral Fracture in Women with Postmenopausal Osteoporosis
2004
Overview
Strontium ranelate, an orally active drug, dissociates bone resorption (which is increased in osteoporosis) from bone formation (which is reduced but continues in osteoporosis). In this randomized, placebo-controlled study of 1649 postmenopausal women with osteoporosis and at least one previous vertebral fracture, fewer subjects receiving strontium ranelate had new vertebral fractures — a 41 percent risk reduction over a three-year period (relative risk, 0.59; 95 percent confidence interval, 0.48 to 0.73).
This orally active drug dissociates resorption from bone formation. The therapy reduced the risk of vertebral fracture.
Vertebral fractures, a serious consequence of osteoporosis, lead to acute and chronic back pain, spinal deformity, and a reduction in survival equivalent to that caused by hip fractures.
1
The health care burden in financial terms is substantial.
2
Vertebral deformities predict further vertebral fracture, even within one year, and also predict nonvertebral fractures.
1
,
3
,
4
The bone fragility that characterizes osteoporosis after menopause results both from an imbalance in bone remodeling at the cellular level, which causes bone resorption to exceed bone formation, and from an increase in the rate of remodeling at the tissue level.
5
Antiresorptive therapies reduce the rate . . .
Publisher
Massachusetts Medical Society,Massachusetts Medical Soc/Nejm
Subject
/ Aged
/ Biological and medical sciences
/ Biopsy
/ Clinical Trials, Phase III as Topic
/ Diseases of the osteoarticular system
/ Female
/ Fractures, Spontaneous - prevention & control
/ Humans
/ Lumbar Vertebrae - diagnostic imaging
/ Organometallic Compounds - adverse effects
/ Organometallic Compounds - pharmacology
/ Organometallic Compounds - therapeutic use
/ Osteoporosis, Postmenopausal - complications
/ Osteoporosis, Postmenopausal - drug therapy
/ Osteoporosis. Osteomalacia. Paget disease
/ Risk
/ Sciences de la santé humaine
/ Spinal Fractures - prevention & control
/ Thiophenes - adverse effects
/ Thiophenes - therapeutic use
/ Thoracic Vertebrae - diagnostic imaging
